actrims action center

Guest: Nancy Chiaravalloti, PhD

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Guest: Nancy Chiaravalloti, PhD

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Guest: Nancy Chiaravalloti, PhD

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Guest: Nancy Chiaravalloti, PhD

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Guest: Robert Motl, PhD

Rehabilitation training for multiple sclerosis patients aims to improve mobility, cognitive function, and quality of life. But one of the largest barriers to having more high-quality randomized control trials of rehabilitation in MS is that most researchers could not be following a stage of different research approaches. So addressing the unmet needs in rehabilitation research is needed to make MS interventions more powerful. You’ll learn more in this episode with Dr. Robert Motl, Professor in the Department of Kinesiology and Nutrition with a secondary appointment in the Department of Rehabilitation Sciences at the University of Illinois Chicago.

Guest: Robert Motl, PhD

Rehabilitation training for multiple sclerosis patients aims to improve mobility, cognitive function, and quality of life. But one of the largest barriers to having more high-quality randomized control trials of rehabilitation in MS is that most researchers could not be following a stage of different research approaches. So addressing the unmet needs in rehabilitation research is needed to make MS interventions more powerful. You’ll learn more in this episode with Dr. Robert Motl, Professor in the Department of Kinesiology and Nutrition with a secondary appointment in the Department of Rehabilitation Sciences at the University of Illinois Chicago.

Guest: Robert Motl, PhD

Rehabilitation training for multiple sclerosis patients aims to improve mobility, cognitive function, and quality of life. But one of the largest barriers to having more high-quality randomized control trials of rehabilitation in MS is that most researchers could not be following a stage of different research approaches. So addressing the unmet needs in rehabilitation research is needed to make MS interventions more powerful. You’ll learn more in this episode with Dr. Robert Motl, Professor in the Department of Kinesiology and Nutrition with a secondary appointment in the Department of Rehabilitation Sciences at the University of Illinois Chicago.

Guest: Yinan Zhang, MD

Chronological age is the biggest early driver of disease progression in patients with multiple sclerosis (MS). That’s why a team of researchers wanted to explore whether biomarkers like p16 and the epigenetic clock can be used to assess biological aging in patients with MS. They found that while patients with MS are aging faster than people without MS based on the epigenetic clock biomarker, no chronological age correlation in p16 expression has been identified in patients with MS. Dive further into these findings with Dr. Yinan Zhang, an Assistant Professor of Neurology at Ohio State University who presented this research at the 2024 ACTRIMS Forum.

Guest: Yinan Zhang, MD

Chronological age is the biggest early driver of disease progression in patients with multiple sclerosis (MS). That’s why a team of researchers wanted to explore whether biomarkers like p16 and the epigenetic clock can be used to assess biological aging in patients with MS. They found that while patients with MS are aging faster than people without MS based on the epigenetic clock biomarker, no chronological age correlation in p16 expression has been identified in patients with MS. Dive further into these findings with Dr. Yinan Zhang, an Assistant Professor of Neurology at Ohio State University who presented this research at the 2024 ACTRIMS Forum.

Guest: Marisa McGinley, DO

The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.

Guest: Marisa McGinley, DO

The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.

Guest: Marisa McGinley, DO

The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.

Guest: Yinan Zhang, MD

Chronological age is the biggest early driver of disease progression in patients with multiple sclerosis (MS). That’s why a team of researchers wanted to explore whether biomarkers like p16 and the epigenetic clock can be used to assess biological aging in patients with MS. They found that while patients with MS are aging faster than people without MS based on the epigenetic clock biomarker, no chronological age correlation in p16 expression has been identified in patients with MS. Dive further into these findings with Dr. Yinan Zhang, an Assistant Professor of Neurology at Ohio State University who presented this research at the 2024 ACTRIMS Forum.

Guest: J. William Lindsey

Epstein-Barr virus (EBV) has long been associated with multiple sclerosis (MS), but a recent study from UTHealth Houston has shed light on its role in the development of MS. To learn more on what we know about EBV-specific T-cells, join Dr. J. William Lindsey, Senior Author of the study, titled UTHealth Houston Study: EBV-specific T-cells play key role in development of multiple sclerosis, and Professor in the Department of Neurology and Director of the Division of Multiple Sclerosis and Neuroimmunology with McGovern Medical School at UTHealth Houston.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stefano Pluchino, MD, PhD

An international collaborative phase 1 study has shown that the injection of a specific form of stem cells into the brains of patients with progressive multiple sclerosis is safe and effective in preventing further brain damage. However, a different type of clinical trial is needed to address whether an advanced cell therapy made of brain-specific stem cells is indeed leading to amelioration of disease features. Take a deeper look into the findings from this study as Dr. Charles Turck speaks with the author of the study, Dr. Stefano Pluchino, Professor of Regenerative Neuroimmunology and Honorary Consultant in Neurology in the Department of Clinical Neurosciences at Cambridge University.